CoChat

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Coleman, Robert L., Sill, Michael W., Thaker, Premal H., Bender, David P., Street, Daron, McGuire, William P., Johnston, Carolyn M., Rotmensch, Jacob · 2015 · Gynecologic Oncology
Cited by 64

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2015.04.005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 22

  1. Jemal, 2008, Cancer statistics, 2008, CA Cancer J. Clin., 58, 71, 10.3322/CA.2007.0010 · DOI · Paper page
  2. Ahn, 2001, Pharmacologic inhibitors of MKK1 and MKK2, Methods Enzymol., 332, 417, 10.1016/S0076-6879(01)32219-X · DOI
  3. Lewis, 2000, Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry, Mol. Cell, 6, 1343, 10.1016/S1097-2765(00)00132-5 · DOI · Paper page
  4. Yeh, 2007, Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor, Clin. Cancer Res., 13, 1576, 10.1158/1078-0432.CCR-06-1150 · DOI · Paper page
  5. Farley, 2013, Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study, Lancet Oncol., 14, 134, 10.1016/S1470-2045(12)70572-7 · DOI · Paper page
  6. Bell, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
  7. Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 92, 205, 10.1093/jnci/92.3.205 · DOI · Paper page
  8. Aghajanian, 2011, Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study, J. Clin. Oncol., 29, 2259, 10.1200/JCO.2010.32.6397 · DOI · Paper page
  9. Kaplan, 1958, Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc., 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
  10. Mehta, 1983, A network algorithm for performing fisher's exact test in r x c contingency tables, J. Am. Stat. Assoc., 78, 427
  11. Cox, 1972, Regression models and life tables, J. R. Stat. Soc. Ser. B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
  12. Naz, 2012, Regulation of S100A2 expression by TGF-beta-induced MEK/ERK signalling and its role in cell migration/invasion, Biochem. J., 447, 81, 10.1042/BJ20120014 · DOI
  13. Jing, 2012, Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212, Mol. Cancer Ther., 11, 720, 10.1158/1535-7163.MCT-11-0505 · DOI · Paper page
  14. Ventura, 2010, Activation of the MEK-S6 pathway in high-grade ovarian cancers, Appl. Immunohistochem. Mol. Morphol., 18, 499, 10.1097/PAI.0b013e3181e53e1c · DOI
  15. Meng, 2009, High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886), Cancer Biol. Ther., 8, 2073, 10.4161/cbt.8.21.9844 · DOI
  16. Sebolt-Leopold, 2003, Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition, Methods Mol. Med., 85, 31
  17. Pavlidou, 2014, Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer, ScientificWorldJournal, 709736
  18. Oza, 2011, A randomized phase II (RP2) trial of ridaforolimus (r) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma, Proc. Am. Soc. Clin. Oncol., 29
  19. Fleming, 2014, Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study, Gynecol. Oncol., 132, 585, 10.1016/j.ygyno.2014.01.015 · DOI
  20. Myers, 2013, Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC), J. Clin. Oncol., 31, 10.1200/jco.2013.31.15_suppl.5524 · doi:10.1200/jco.2013.31.15_suppl.5524
  21. Gonzalez-Billalabeitia, 2014, Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition, Cancer Discov., 8, 896, 10.1158/2159-8290.CD-13-0230 · DOI · Paper page
  22. Mendes-Pereira, 2009, Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors, EMBO Mol. Med., 1, 315, 10.1002/emmm.200900041 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Coleman, R. L., Sill, M. W., Thaker, P. H., Bender, D. P., Street, D., McGuire, W. P., Johnston, C. M., & Rotmensch, J.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2015-07
Volume
138
Issue
1
Pages
30-35
ISSN
0090-8258
Cited by
64
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Cancer Institute (1 U10 CA180822, CA 27469, CA 37517)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. https://app.cochat.ai/papers/10.1016/j.ygyno.2015.04.005
The paper
Coleman, R. L., Sill, M. W., Thaker, P. H., Bender, D. P., Street, D., McGuire, W. P., Johnston, C. M., & Rotmensch, J. (2015). A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2015.04.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.